Tamoxifen is one of highly successful adjuvant endocrine drug for over 30 year due to its abundant, mature safety data in clinical [5] and function as an antagonist via competition with estradiol to bind to ERα and modulation of gene expression for ERα-positive breast cancer cells [37, 38]. The gene discussed is ESR1; the disease is breast cancer.